Glycomine, Inc. has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GLM101, a mannose-1-phosphate replacement therapy being developed for the treatment of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). This designation aims to expedite the development and review of GLM101, addressing a critical unmet medical need for patients with this rare genetic disorder.
Clinical Trial Progress
The GLM101-002 Phase 2 clinical study (NCT05549219) has enrolled 10 adult and five adolescent patients with PMM2-CDG in the U.S. and Spain. Participants have been treated with GLM101 at doses of 10 mg/kg (n=3), 20 mg/kg (n=3), or 30 mg/kg (n=9) for up to 24 weeks. To date, over 350 doses of GLM101 have been administered. The study is ongoing and plans to include pediatric patients aged 2 years and older.
Safety and Tolerability
According to Glycomine, GLM101 has demonstrated a favorable safety profile in the ongoing Phase 2 study. The drug appears to be well-tolerated, with no serious adverse events reported. Only mild to moderate adverse events have been observed, suggesting a manageable safety profile for patients undergoing treatment.
Mechanism of Action and Orphan Drug Status
PMM2-CDG, previously known as CDG Type Ia, is caused by genetic mutations leading to a deficiency in the phosphomannomutase 2 enzyme, which is encoded by the PMM2 gene. GLM101 is designed to bypass this enzyme deficiency by delivering mannose-1-phosphate directly into cells, thereby restoring pathway function. GLM101 has been granted Orphan Drug Designation in both the U.S. and Europe, as well as Rare Pediatric Disease Designation in the U.S., highlighting the urgent need for effective therapies for this rare condition.
Implications of Fast Track Designation
The FDA's Fast Track program is designed to accelerate the development and review of potential therapies for serious conditions with unmet medical needs. Glycomine will benefit from more frequent interactions with the FDA during the clinical development of GLM101. This designation also makes GLM101 eligible for accelerated approval and priority review, contingent upon meeting the relevant criteria. "Fast Track Designation for GLM101 highlights its potential to meet the serious unmet medical need of patients with PMM2-CDG," said Rose Marino, M.D., Chief Medical Officer of Glycomine. "As we continue to enroll pediatric patients in our Phase 2 clinical study, we are encouraged by our initial data showing promising evidence of clinical benefit with GLM101. We look forward to progressing development of GLM101 within the Fast Track framework."
